Eisai enters an agreement with Gilead Sciences to commercialise filgotinib in Asia.
In December 2019, Eisai signed a partnership agreement with Gilead Sciences K.K., a Japanese subsidiary of Gilead, for the distribution and co-promotion of filgotinib in Japan.
Under the terms of the new agreement, Eisai will obtain an exclusive marketing right for filgotinib in South Korea, Taiwan, Hong Kong and Singapore from Gilead. Gilead has received approval for the treatment of RA in Taiwan and has applied for approval of filgotinib for the treatment of RA in South Korea. Following approvals, Eisai will take over the manufacturing and marketing licenses for filgotinib from Gilead in South Korea and Taiwan. In Hong Kong and Singapore, Eisai will apply for approval for filgotinib. With this agreement, Eisai will pay Gilead a contractual up-front payment, as well as regulatory milestones and sales milestones.
Related news and insights
Scynexis, Inc. announced that the FDA has approved a second indication for Bexafemme (ibrexafungerp tablets) for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC)
Eli Lilly and Company has announced that donanemab met all primary and secondary endpoints for the 6-month primary outco me analysis in the Phase III TRAILBLAZER-ALZ 4 study , providing the first active comparator data on amyloid plaque clearance in patients with early symptomatic Alzheimer's disease treated with amyloid-targeting therapies